• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Provident Financial Services

Provident Financial Services

Provident Financial Services Inc PFS

Last Price$21.23Day Change (%)-0.28%
Open Price$21.20Day Change ($)-0.06
Day Range21.10–21.3452-Week Range17.71–21.72

As of Fri 9/23/2016 5:28:00 PM | USD

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. European Commission Approves Ipsen’s Cabometyx™ (Cabozantinib) Tablets for the Treatment of Advanced Renal Cell Carcinoma (RCC) in Adults Following Prior Vascular Endothelial Growth Factor ...

    European Commission Approves Ipsen’s Cabometyx™ (Cabozantinib) Tablets for the Treatment of Advanced Renal Cell Carcinoma (RCC) in Adults Following Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Therapy

  2. European Commission Approves CABOMETYX™ (cabozantinib) Tablets for the Treatment of Advanced Renal Cell Carcinoma Following VEGF-Targeted Therapy

    European Commission Approves CABOMETYX™ (cabozantinib) Tablets for the Treatment of Advanced Renal Cell Carcinoma Following VEGF-Targeted Therapy

  3. Pfizer Receives Positive CHMP Opinion For IBRANCE® (palbociclib) In Combination With Endocrine Therapy For The Treatment Of HR+/HER2- Metastatic Breast Cancer In Europe

    Pfizer Receives Positive CHMP Opinion For IBRANCE® (palbociclib) In Combination With Endocrine Therapy For The Treatment Of HR+/HER2- Metastatic Breast Cancer In Europe

  4. World’s Leading Packet Flow Switch Adds High-Density 40G for Large-Scale Enterprise and Service Provider Networks

    World’s Leading Packet Flow Switch Adds High-Density 40G for Large-Scale Enterprise and Service Provider Networks

  5. FDA Accepts Supplemental Biologics License Application, Assigns Priority Review and Grants Breakthrough Therapy Designation to Merck’s KEYTRUDA® (pembrolizumab) for First-Line Treatment of Patients ...

    FDA Accepts Supplemental Biologics License Application, Assigns Priority Review and Grants Breakthrough Therapy Designation to Merck’s KEYTRUDA® (pembrolizumab) for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer

  6. Phase III Study Showed Genentech’s Cancer Immunotherapy TECENTRIQ™ (Atezolizumab) Helped People with a Specific Type of Lung Cancer Live Significantly Longer Compared to Chemotherapy

    Phase III Study Showed Genentech’s Cancer Immunotherapy TECENTRIQ™ (Atezolizumab) Helped People with a Specific Type of Lung Cancer Live Significantly Longer Compared to Chemotherapy

  7. NAPFA’s CFP-Only Stand: A Step in the Wrong Direction

    A curious move, at a curious time, for purportedly, a curious reason, that is also a slap in the face to CPAs with the PFS credential.

  8. Reasons for Optimism

    This article represents opinions of the author and not those of his firm and are subject to change from time to time and do not constitute a recommendation to purchase and sale any security nor to engage in any particular investment strategy. The information contained here has been obtained from ...

  9. Forward-Looking Broad-Market Investing

    Before investing you should carefully consider the Fund’s investment objectives, risks, charges and expenses. This and other information is in the prospectus. Please read the prospectus carefully before you invest. Foreside Fund Services, LLC, Distributor. An investment in the Funds is subject to ...

  10. What’s Wrong With Indexes?

    To the extent that this content includes references to securities, those references do not constitute an offer or solicitation to buy, sell or hold such security. AdvisorShares is a sponsor of actively managed exchange-traded funds (ETFs) and holds positions in all of its ETFs. This document should ...

123
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.